Breakthroughs Blog

Breakthroughs brings you stories of bright ideas and bold innovations in global health.

The Latest
Ansley Kahn
Research Roundup: Vaccines without chemicals, FDA fast track for Vanelva's chikungunya vaccine, and Marburg virus found in bats in West Africa

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Recent

10 reasons why the US policymakers should support global health research and development

At the Global Health Technologies Coalition, our mission is to advance—through advocacy—the research and development (R&D) of new tools to prevent, diagnose, and treat global diseases.

Read More
PATH/Evelyn Hockstein
Research Roundup: Experimental Ebola vaccines and treatments, HIV prevention research, and an 18-year high in drug approvals

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
Budget compromise reached: How did global health R&D fare?

Working over a rare weekend session and racing against the clock to keep the government open, Congress finally came to an agreement on a year-long spending plan to fund the government through September 30, 2015 (with the exception of the Department of Homeland Security, which only goes through February 27).

GHTC
Read More
CDC/James Gathaney
Research Roundup: R&D funding for neglected diseases, antimicrobial drug resistance, immunity for Ebola vaccine makers, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Aaron Joel Santos
Research Roundup: a weakened HIV virus, SDGs, powdered measles vaccine, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Doune Porter
Research Roundup: Gates Foundation open access policy, Ebola vaccine market, World AIDS Day, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
PATH/Evelyn Hockstein
Research Roundup: Drug development costs, the price of priority review, new clinical trial requirements, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
Ten global health advancements I’m thankful for this Thanksgiving

As global health advocates, our work often requires us to focus on unmet needs—such as the number of people worldwide who still die from preventable diseases each year, or the lack of adequate resources and investment to tackle these diseases.

Read More
PATH/Eric Becker
Research Roundup: Malaria eradication, indemnity for Ebola vaccine manufacturers, drug development impediments, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
#CoughUpTheTBMoney: TB activists call for tripling annual spending on TB research

In this guest post, Mike Watson Frick—TB/HIV program officer at Treatment Action Group (TAG)—writes about the state of tuberculosis (TB) research funding and civil society actions that took place at the recent Union World Conference on Lung Health in Barcelona, Spain.

Read More
Election results are in: Here’s what happened and how it could impact global health R&D

Election night saw an historic shift in Congress, with Republicans extending their majority in the House of Representatives and capturing the Senate for the first time since 2006.

GHTC
Read More
Research Roundup: Midterm elections, Ebola legislation, HIV prevention research, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
How the upcoming election could impact global health R&D

As candidates make their final pitches, volunteers canvas like crazy, and pollsters make their predictions, GHTC is taking a look at what the outcomes of next week’s election could mean for global health research and development (R&D).

GHTC
Read More
HIV Vaccines and Microbicides Resource Tracking Working Group
First-ever conference devoted solely to HIV prevention R&D taking place in uncertain funding environment

Progress toward new tools to prevent HIV infection—including vaccines, microbicides, the use of antiretroviral treatment as HIV prevention, pre-exposure prophylaxis (PrEP), and a host of other options—is being presented and discussed at the inaugural HIV Research for Prevention Conference (HIVR4P) in Cape Town this week.

AVAC
Read More
FDA/Michael J. Ermarth
Four reasons you should check out the Global Health Regulatory Requirements Database

Navigating global regulatory processes is a critical component to the development and introduction of global health technologies.

PATH
Read More
PATH/Evelyn Hockstein
Research Roundup: Ebola vaccine hurdles, SDG financing, blocking malaria transmission, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
PATH/Aaron Joel Santos
Research Roundup: hookworm vaccine trial, Grand Challenges turns ten, NIH funding for Ebola and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
PATH/Heng Chivoan
Research Roundup: Intellectual property awards, FDA priorities, Australia R&D, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
PATH/Satvir Malhotra
Research Roundup: R&D in the post-2015 agenda, TB vaccines, the Global Innovation Fund, intellectual property, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
Making the case for research and innovation for health in the post-2015 development agenda

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper exploring why research and development (R&D) of high-priority health tools for diseases and conditions affecting low- and middle-income countries (LMICs) should be a critical component of the post-2015 development agenda.

PATH
Read More